HIV Safety in Clinical Laboratories: Biology, Occupational Risk, Prevention, and Florida Law

Issues of Concern

Modes of HIV Transmission

Occupational exposures

HIV transmission occurs through direct exposure to infected blood or secretions. This can happen in an occupational setting through accidental needlesticks or sharp-object cuts.[4] Developing HIV after a needlestick injury is uncommon, and studies have revealed that the risk of transmission is 0.3%. This can be higher if the patient has a high viral titer or if exposure to a large quantity of infected blood has occurred. Additionally, transmission may occur when infected blood splashes onto mucosal surfaces.[9]

Potentially infectious body fluids

Exposure to blood or other bodily fluids, including vaginal secretions, semen, cerebrospinal fluid (CSF), peritoneal fluid, pleural fluid, and amniotic fluid, can expose healthcare workers to bloodborne pathogens like HIV.[10]

Risk Factors Associated with Increased HIV Infection

Following established recommendations and protocols is necessary to decrease the risk of occupational exposure to HIV infection. Factors associated with increased risk include:

• Lack of universal precautions
• Failure to follow safety protocol
• Use of sharp devices without safety features
• Exposure to a higher quantity of blood or a large-bore needle [9]

Practices that Prevent HIV Exposure

HIV has no vaccine. However, prevention of HIV exposure is the best way to prevent transmission in the healthcare setting. Among healthcare laboratory personnel, bloodborne viruses are responsible for most laboratory-acquired infections. Education, training, and biosafety protocols should be in place to reduce the potential risk of disease transmission.[11]

Engineering controls

Engineering controls are tools designed to remove contaminated equipment from the workplace.[10] Proper use of safety-engineered devices reduces the risk of accidental exposure to HIV, including:

• Dispose of sharps in sharps containers 
• Avoid recapping used needles
• Use shields and retractable needles
• Use plastic blood tubes instead of glass [12][13][14]

Exposure prevention is critical to preventing the transmission of HIV and other bloodborne pathogens.

Sharps

Sharp injuries may result from needles, scalpels, razors, or lancets. All sharps must be disposed of in a specified, puncture-proof container.[10][12]

Work practice controls

These controls reduce exposure to bloodborne pathogens.[10][15] When an exposure risk is identified,

• Wear gloves when there is direct contact with blood and bodily fluids.
• Wear masks, eyeglasses, and waterproof gowns during procedures where blood splashing may occur.
• Do not perform mouth pipetting.
• Avoid contact with mucosal surfaces, such as eating, drinking, smoking, applying lip balm, or handling contact lenses.

Handwashing

Proper hand hygiene is one of the most effective ways to control infection and prevent disease transmission after exposure. CDC guidelines recommend handwashing with soap and water for 20 seconds or using an alcohol hand rub with 60% alcohol. Hand hygiene should occur after touching a patient, cleaning a soiled site, contacting bodily fluids, and touching contaminated surfaces.[10]

Personal protective equipment

Personal protective equipment (PPE) is essential in the laboratory, as this practice protects healthcare workers from potential exposure by creating a physical barrier. Basic PPE includes masks, gowns or coats, gloves, and face shields.[10]

Gloves

Healthcare workers must wear gloves when encountering bodily fluids, collecting blood or fluids, and contacting contaminated surfaces. Gloves must be changed if they are torn, damaged, or contaminated. They must also be changed before leaving the work area and between patient encounters.

Disinfection

HIV can persist on dry surfaces for more than 7 days.[16] The organic materials should be removed from the surface before cleaning. Many disinfectant solutions are effective against HIV. Most commonly, UV-LED light, 70% ethyl alcohol, or sodium hypochlorite (household bleach) can inactivate HIV on surfaces.[17][18] Reading the product's label is important to ensure activity against HIV.

Clinical Significance

Clinical Management of an HIV Exposure

Exposure

If exposure occurs, a healthcare worker must get emergency care, and first aid should be started. The type of care depends on the route of exposure. If the nose, mouth, face, or skin is exposed, they should be flushed with water. Additionally, if exposure occurs to the eyes, they should be irrigated with sterile saline, sterile irrigation solution, or clean water. For needlestick or cut exposure, the site should be washed with soap and water, and wounds must be cleaned.[9] Healthcare workers should promptly report HIV exposure to their supervisors, and medical evaluation with management should follow.[10]

Evaluation and treatment

Medical evaluation and decision to treat should occur immediately, and a plan for postexposure prophylaxis should be ensured. Follow-up evaluations should occur. The healthcare worker’s health information is kept confidential.[19] If possible, the CDC recommends testing the source patient with an FDA-approved rapid HIV test. Fourth-generation combination p24 antigen-HIV antibody (Ag/Ab) tests provide rapid, accurate results and are preferred over older-generation tests. Serum creatinine, AST, and ALT should also be tested as part of the baseline workup.[20]

Postexposure Prophylaxis

If possible, the source patient should be tested for HIV. Expert consultation is suggested.[1][21] ART must be started as soon as possible, preferably within 72 hours of exposure, and continued for 4 weeks, and should be initiated while awaiting the source patient's results and continued for 28 days, with follow-up at 4 and 12 weeks.[21] Postexposure prophylaxis (PEP) regimens typically consist of 3 drugs with low adverse effects and minimal risk of development of HIV resistance. Routine laboratory tests are not needed to assess for ART drug toxicity during the duration of treatment. PEP can be discontinued if the source patient is determined to be negative for HIV (see Image. Postexposure Prophylaxis for HIV).[21] 

Care and Treatment of HIV/AIDS Patients

Risks and behaviors associated with HIV/AIDS

HIV can be transmitted through bodily secretions through sexual contact, blood, and pregnancy.[22] Specific risk behaviors can increase the chance of disease transmission, including:

• Injection and noninjection drug use
• Unprotected sex
• Multiple sexual partners
• Exchange of sex for money or drugs
• Use of alcohol or drugs before or during sexual intercourse [23]

HIV cannot be transmitted through casual contact with saliva, eg, kissing, spitting, or sharing drinks.[24]

Goals of HIV/AIDS treatment

Currently, HIV has no vaccine or cure, though clinical trials and studies continue to be performed. ART, when started early, has enabled people with HIV to live long lives with chronic infection.[2] The Centers for Disease Control and Prevention (CDC) aims to implement a 95-95-95 plan, where 95% of people infected with HIV have been diagnosed, 95% with diagnosed infection are on ART, and 95% of those on ART have decreased viral load.[25]

Antiretroviral treatment for patients infected with HIV

Individuals should be tested for drug resistance before beginning treatment with ART, allowing physicians to choose the most effective medications.[26] ART should be started immediately, regardless of CD4 cell count or viral load. The World Health Organization (WHO) advises a 1-month course of ART with at least 3 medications as postexposure prophylaxis.[27]

Benefits of ART include:

• Better clinical outcomes
• Decrease in viral load and transmission
• Delay in disease progression
• Reduced morbidity and mortality
• Prevention of immune system decline [28]

Limitations of ART include:

• Daily adherence
• Long-term medication toxicity
• Cost of treatment
• Limited options for those with multiclass resistance [29]

Types of ART medications

Each medication targets a step in the HIV lifecycle. A combination of different classes is used to treat patients with HIV, including:

• Entry inhibitors: maraviroc, fostemsavir, ibalizumab
• Capsid inhibitors: lenacapavir
• Nucleoside reverse transcriptase inhibitors (NRTI): lamivudine, abacavir, emtricitabine, zidovudine
• Nucleotide reverse transcriptase inhibitors (NtRTI): tenofovir (TAF, TDF)
• Non-nucleoside reverse transcriptase inhibitors (NNRTI): doravirine, efavirenz, nevirapine, rilpivirine, etravirine
• Integrase inhibitors: raltegravir, elvitegravir (first generation); bictegravir, cabotegravir, dolutegravir (second generation)
• Protease inhibitors: ritonavir, darunavir, atazanavir, tipranavir 
• Pharmacokinetic enhancers: cobicistat, ritonavir [2][30][NIH Office of AIDS Research Advisory Council. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2025]

Attitude and Stigma Associated with HIV/AIDS

HIV/AIDS stigma

HIV/AIDS stigma remains a barrier to accessing medical care, prevention, and therapy. Manifestations of stigma vary across cultures, societal beliefs, and group norms. Structural violence (racism, sexism, poverty) coupled with a preexisting stigma against high-risk groups (injection drug users, sex workers, men who have sex with men) enhances the power stigma has on the HIV/AIDS epidemic, ultimately leading to decreased diagnosis, treatment, and care. Stigma arises from a convergence of labeling, stereotyping, separating, and discriminating.[31]

Counteracting HIV/AIDS Stigma

Strategies to counteract HIV/AIDS stigma include:

• Understand how HIV is transmitted and who can become infected.
• Advocate for laws and policies to end the stigma against men who have sex with men, sex workers, injection drug users, and migrants.
• Support organizations rallying to end discrimination against people infected with HIV.
• Assist families and communities of those infected or affected.
• Learn about legal consequences and policy actions.
• Support routine HIV testing.[31]

Other Issues

Current Florida Law on AIDS and the Impact on HIV Testing

Legislative intent

The Florida legislature designs laws regarding HIV and other sexually transmitted diseases to provide patients with privacy, confidentiality, and dignity.

Informed consent

Informed consent for HIV testing must include an explanation to the patient regarding confidentiality, mandatory reporting, and the opportunity for anonymous testing. Florida statutes maintain that in a healthcare setting, a patient must be notified of a planned HIV test, and they have the right to refuse the test, which will be documented in the patient’s chart. If they have signed a general consent form for medical care, a separate consent for an HIV test is not required. In a non-healthcare setting, specific informed consent for HIV testing is required. A legal guardian may provide informed consent if a person is incompetent, incapacitated, or a legal minor.

Confidentiality

Information regarding a person’s HIV status must be kept confidential, except for the following:

• The patient gives consent
• Given for statistical purposes and excluding identifying information
• Made to mandatory reporting to medical personnel, state agencies, or mandated court jurisdiction
• Disclosed during a medical emergency, only sharing relevant information for the patient’s care

If an individual violates confidentiality, the person commits a first-degree misdemeanor, punishable by a fine of up to $1,000 and up to 1 year in prison. Any person who spreads information about an individual with HIV or another sexually transmitted disease for monetary gain or with malicious intent commits a felony in the third degree. This is punishable by a fine of up to $5,000 or imprisonment of up to 5 years.

Reporting Results

The Florida Department of Health will keep information confidential and private. The diagnosis of HIV or AIDS must be reported to the Florida Department of Health within 2 weeks of the positive test result. Any positive HIV or AIDS results must be reported using the system developed by the CDC or an equivalent system to ensure confidentiality. The Department of Health may fine anyone who fails to report HIV or AIDS up to $500 for each offense, and a regulatory agency will be informed of the violation.[Florida State Statutes. Title XXIX Public Health, Chapter 381 Public Health: General Provisions. 2025]

Preliminary and Confirmatory Testing

In 2014, the CDC updated testing guidelines. They recommend screening with an HIV-1/2 antigen/antibody test. If screening is nonreactive, no further testing is required. If HIV-1/2 antigen/antibody testing is reactive, an HIV-1/HIV-2 antibody differentiation test is recommended. If the differentiation test is nonreactive or indeterminate, a qualitative HIV-1 RNA test is recommended to confirm the results (see Image. HIV Diagnostic Algorithm).[32] 

Enhancing Healthcare Team Outcomes

HIV is a retrovirus transmitted through exposure to infected blood and body fluids that targets CD4+ T cells, leading to progressive immune dysfunction. Early infection may present with nonspecific symptoms such as fever, lymphadenopathy, rash, and myalgia, followed by an asymptomatic phase characterized by ongoing viral replication and declining CD4+ counts. Without treatment, this progression increases the risk of opportunistic infections and malignancies, defining acquired immunodeficiency syndrome. Diagnosis relies on fourth-generation antigen-antibody testing, with confirmatory assays as indicated. Early initiation of antiretroviral therapy improves survival, reduces viral transmission, and prevents disease progression. Prompt recognition and management of occupational exposures, including timely initiation of postexposure prophylaxis, remain essential to reducing transmission risk. This includes the development and enforcement of standardized protocols, the adoption of safety-engineered medical devices, and the establishment of continuous training programs focused on infection prevention and control.[33]

Interprofessional collaboration enhances patient-centered outcomes through coordinated prevention, diagnosis, and management.  Nurses, technicians, and phlebotomists are primarily responsible for the safe collection and initial handling of blood and tissue samples, ensuring adherence to standard precautions. Laboratory personnel play a critical role in maintaining biosafety during sample processing, testing, and disposal. Physicians and advanced practitioners oversee clinical decision-making, while pharmacists contribute to the appropriate selection and management of PEP when indicated. Effective communication, shared decision-making, and timely referral strengthen adherence, reduce complications, and promote comprehensive, systems-based HIV care.

From an ethical perspective, maintaining confidentiality, ensuring informed decision-making, and fostering a culture of safety are paramount. Protecting healthcare workers from occupational exposure not only safeguards their well-being but also directly contributes to patient safety by reducing the risk of bidirectional transmission. Ultimately, coordinated care, continuous education, adherence to safety protocols, and strong communication among all team members enhance overall healthcare outcomes, improve laboratory safety standards, and support a high-performing, patient-centered care environment.